Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study

Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hasniza Zaman Huri, NorFarahen Selamat, Shireene Ratna Vethakkan
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2014/367564
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554906655916032
author Hasniza Zaman Huri
NorFarahen Selamat
Shireene Ratna Vethakkan
author_facet Hasniza Zaman Huri
NorFarahen Selamat
Shireene Ratna Vethakkan
author_sort Hasniza Zaman Huri
collection DOAJ
description Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabetes mellitus. This retrospective study was conducted to address the utilization pattern of DPP-4 inhibitors and factors that influence choice in type 2 diabetes mellitus patients. 299 subjects taking either sitagliptin or vildagliptin from September 2008 to September 2012 were included in the study. Sitagliptin was more frequently prescribed than vildagliptin. Of the patients prescribed DPP-4 inhibitors, 95% received combinations of these and other agents, whereas only 5% were prescribed DPP-4 inhibitors as monotherapy. Factors affecting the utilization of DPP-4 inhibitors included age (P=0.049) and concomitant use of beta blockers (P=0.045) and aspirin (P=0.008). Early identification of factors associated with DPP-4 inhibitors is essential to enhance quality use of the drugs.
format Article
id doaj-art-5089517480f84c9eb6390491ef6d7bee
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-5089517480f84c9eb6390491ef6d7bee2025-02-03T05:50:13ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/367564367564Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective StudyHasniza Zaman Huri0NorFarahen Selamat1Shireene Ratna Vethakkan2Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaDepartment of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaEndocrinology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaDipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabetes mellitus. This retrospective study was conducted to address the utilization pattern of DPP-4 inhibitors and factors that influence choice in type 2 diabetes mellitus patients. 299 subjects taking either sitagliptin or vildagliptin from September 2008 to September 2012 were included in the study. Sitagliptin was more frequently prescribed than vildagliptin. Of the patients prescribed DPP-4 inhibitors, 95% received combinations of these and other agents, whereas only 5% were prescribed DPP-4 inhibitors as monotherapy. Factors affecting the utilization of DPP-4 inhibitors included age (P=0.049) and concomitant use of beta blockers (P=0.045) and aspirin (P=0.008). Early identification of factors associated with DPP-4 inhibitors is essential to enhance quality use of the drugs.http://dx.doi.org/10.1155/2014/367564
spellingShingle Hasniza Zaman Huri
NorFarahen Selamat
Shireene Ratna Vethakkan
Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
International Journal of Endocrinology
title Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
title_full Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
title_fullStr Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
title_full_unstemmed Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
title_short Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
title_sort factors associated with utilization of dipeptidyl 4 inhibitors in patients with type 2 diabetes mellitus a cross sectional retrospective study
url http://dx.doi.org/10.1155/2014/367564
work_keys_str_mv AT hasnizazamanhuri factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy
AT norfarahenselamat factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy
AT shireeneratnavethakkan factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy